Noile-Immune Biotech Inc. (4893) Stock Price & Analysis

4893 Stock Chart & Stats

¥82.00-¥3.00(-3.53%)

At close: Nov 02 3:30 PM GMT+9

Day’s Range: JPY 83.00 - JPY 87.00
52-Week Range: JPY 83.00 - JPY 217.00
Previous Close: JPY 87.00
Volume: N/A
Average Volume (3M): 262.39K
Market Cap: JPY 3.69B
Enterprise Value: JPY 1.70B
Total Cash (Recent Filing): JPY 3.54B
Total Debt (Recent Filing): JPY 0
Price to Earnings (P/E): ―
Beta: 0.80
Next Earnings: Nov 13, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

The absence of debt reduces leverage, interest, and refinancing pressure, giving the company more financial flexibility while it develops its biotechnology programs. Although ongoing losses are eroding equity, a debt-free structure provides a more resilient base than a similarly unprofitable business carrying significant borrowings.

High Gross Margin

A consistently near-100% gross margin indicates that reported revenue has historically carried little direct cost burden. If revenue can stabilize and recover, this structure could provide operating leverage because incremental sales may contribute substantially toward fixed expenses, although current losses show that scale is not yet sufficient.

Narrower Annual Loss

The reduction in net loss during 2025 offers a modest sign that the pace of earnings deterioration may have eased from the prior year. If sustained, improving losses could extend the company’s funding runway and gradually support better operating leverage, though profitability remains distant and unproven.

Bears Say

Sharp Revenue Contraction

Repeated revenue contraction weakens the foundation for commercialization and makes the company’s future earnings power difficult to establish. Lower sales also reduce the ability to absorb fixed operating costs, increasing dependence on available funding while management works to restore growth and revenue stability.

Persistent Deep Losses

Deep and recurring losses show that the current business does not yet convert its high gross margin into sustainable profitability. Continued negative margins can consume equity over time, constrain investment choices, and leave future value dependent on successfully improving revenue scale and operating efficiency.

Ongoing Cash Burn

Persistent negative operating cash flow means the company is not self-funding its operations and must rely on existing cash or equity financing. Even without debt, continued burn can reduce financial capacity, increase funding dependence, and limit the resources available for advancing commercialization over the next several quarters.

4893 FAQ

What was Noile-Immune Biotech Inc.’s price range in the past 12 months?

Noile-Immune Biotech Inc. lowest stock price was ¥83.00 and its highest was ¥217.00 in the past 12 months.

What is Noile-Immune Biotech Inc.’s market cap?

Noile-Immune Biotech Inc.’s market cap is ¥3.69B.

When is Noile-Immune Biotech Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Noile-Immune Biotech Inc.’s earnings last quarter?

Noile-Immune Biotech Inc. released its earnings results on Aug 13, 2026. The company reported -¥5.05 earnings per share for the quarter, beating the consensus estimate of -¥5.51 by ¥0.46.

Is Noile-Immune Biotech Inc. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Noile-Immune Biotech Inc. pay dividends?

Noile-Immune Biotech Inc. does not currently pay dividends.

What is Noile-Immune Biotech Inc.’s EPS estimate?

Noile-Immune Biotech Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Noile-Immune Biotech Inc. have?

Noile-Immune Biotech Inc. has 43,399,117 shares outstanding.

What happened to Noile-Immune Biotech Inc.’s price movement after its last earnings report?

Noile-Immune Biotech Inc. reported an EPS of -¥5.05 in its last earnings report, beating expectations of -¥5.51. Following the earnings report the stock price went up 0.714%.

Which hedge fund is a major shareholder of Noile-Immune Biotech Inc.?

Currently, no hedge funds are holding shares in JP:4893

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description